{
  "id": 5634865,
  "title": "Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts",
  "url": "https://urgent.news/2026/09/03/kodiak-sciences-kod-races-toward-three-make-or-break-trial-verdicts",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T10:58:06.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/kodiak-sciences-kod-races-toward-105806803.html"
  },
  "original_language": "en",
  "account": "Kodiak Sciences Inc. (KOD) is on the verge of three critical Phase 3 trial verdicts, which will significantly impact its future. The biotech firm reported a widening cash burn and a $65.6 million net loss in Q2 2026, despite promising data from its two lead candidates, Zenkuda and KSI-101. Zenkuda, already tested in four Phase 3 studies, is set to deliver one-year topline data for wet age-related macular degeneration in September 2026, while KSI-101 in PEAK is evaluating its efficacy in macular edema secondary to inflammation. Kodiak also began enrolling patients in ALTO, a trial testing KSI-501 against aflibercept in diabetic macular edema. These trials will determine whether the company's novel treatments can compete in a $15 billion anti-VEGF market. With three trials due between September and December, any disappointing results could severely impact Kodiak's already thinning equity cushion.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}